AlenCiken

XPro1595 Decreases Neuroinflammation in Patients with Alzheimer’

NASDAQ:INMB   INmune Bio Inc.
INmune Bio, Inc. Announces Interim Phase Ib Data Demonstrating That XPro1595 Decreases Neuroinflammation in Patients with Alzheimer’s Disease

XPro1595 reduces neuroinflammation by 40.6% in a brain fiber pathway important for learning and memory

Interim results from a Phase Ib clinical trial show that treatment with XPro1595 decreases white matter free water, a biomarker of neuroinflammation measured by MRI

The preliminary results from INmune Bio’s Phase Ib study add to the growing enthusiasm for tackling neuroinflammation in the treatment of Alzheimer’s disease.

www.globenewswire.co...eimer-s-Disease.html

면책사항

이 정보와 게시물은 TradingView에서 제공하거나 보증하는 금융, 투자, 거래 또는 기타 유형의 조언이나 권고 사항을 의미하거나 구성하지 않습니다. 자세한 내용은 이용 약관을 참고하세요.